Biotechnology

OSR Holdings Completes Woori IO Acquisition, Secures Long-Term Shareholder Alignment, and Reviews Strategic Combination of Medical Device Subsidiaries

January 27, 2026 8:30 AM

OSR Holdings, Inc. (NASDAQ:OSRH) today announced the official closing of its acquisition of Woori IO, the reaffirmation of long-term equity alignment by Woori IO's historical shareholders, and the initiation of a strategic review regarding a potential combination of its medical device subsidiaries. Woori IO Acquisition Closed OSRH confirmed that the previously announced acquisition of Woori IO and the related share exchange transaction have been...

Read more

Strong DiviTum TKa Results Published in JCO Precision Oncology

January 27, 2026 2:45 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II), a leader in blood-based cancer monitoring, today announced that DiviTum TKa data from the Ciclib trial at Roswell Park have been published in JCO Precision Oncology. Results show that thymidine kinase activity (TKa) measured in blood can predict and dynamically track which patients respond to CDK4/6 inhibitor therapy in HR+/HER2‑ breast cancer. The study evaluated breast cancer...

Read more

Faron Expands Bexmarilimab Program in Solid Tumors with a Randomized Phase I/II BEXAR IIT in Metastatic Soft-Tissue Sarcoma

January 27, 2026 2:20 AM

Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on tackling cancers through novel immunotherapies, today announces a significant expansion to scope of clinical trials where bexmarilimab is investigated by supporting the BEXAR investigator-initiated trial (IIT). Faron continues to leverage its deep understanding of the Clever-1 pathway to address solid tumors. The BEXAR trial evaluates...

Read more

Bora Biologics Celebrates Opening of $30 Million San Diego Manufacturing Expansion

January 26, 2026 12:00 AM

Bora Biologics, a contract drug manufacturing organization specializing in microbial and mammalian expressed therapeutics, celebrated the opening of its expanded FDA approved manufacturing facility in San Diego with a ribbon cutting ceremony attended by company leadership, employees, community partners, and San Diego Mayor Todd Gloria. The $30 million facility expansion adds state of the art upstream and downstream GMP processing capabilities...

Read more

Moolec Science S.A. Receives Nasdaq Staff Memo Supporting Panel Exception Through June 29, 2026 to Regain Compliance with Stockholders' Equity Requirement

January 23, 2026 6:30 PM

Moolec Science S.A. ("Moolec" or the "Company") today announced that Nasdaq Staff has issued a memorandum to the Nasdaq Hearings Panel (the "Panel") concluding that there is sufficient basis to grant Moolec an exception through June 29, 2026 to demonstrate compliance with the stockholders' equity requirement set forth in Nasdaq Listing Rule 5550(b)(1) (the "Stockholders' Equity Requirement"), subject to certain disclosure conditions. The Staff...

Read more

VinFuture Opens Call for Excellent Scientific Breakthroughs for the 6th Season

January 23, 2026 9:03 AM

The VinFuture Prize officially announces the launch of its 2026 season and opens the nomination period until 2:00 PM on April 17, 2026 (Vietnam time, GMT+7). Eligible nominations must pertain to scientific or technological inventions and solutions that demonstrate clear, measurable benefits for millions of people worldwide and must be submitted by distinguished individuals or reputable institutions within the global science and technology...

Read more

Aviwell Closes €11 Million Series A Investment Round to Scale AI‑Driven Microbiota Platform for Sustainable Animal Nutrition

January 23, 2026 12:01 AM

Aviwell SAS, a deep‑tech animal nutrition company headquartered in Toulouse, today announced the successful completion of a €11 million Series A investment round, welcoming three new investors: Blue Revolution Fund (BRF), Blast.Club, and SWEN Capital Partners. The financing will support Aviwell's next phase of growth as the company scales its AI‑driven microbiome discovery and development platform and advances native, nature‑based biological...

Read more

LIR Life Sciences Completes Design of Ex Vivo Animal Study to Evaluate Novel Transdermal Agents for Transport of Larger Therapeutic Molecules

January 22, 2026 6:00 PM

LIR Life Sciences Corp. (CSE:SKNY)(Frankfurt:N790, WKN: A41QA9) ("LIR" or the "Company") is pleased to announce the completion of a study design for an ex vivo porcine skin investigation that is designed to evaluate whether novel transdermal agents can enhance the transdermal penetration of therapeutic macromolecules across a wide molecular size range, spanning approximately 5kDa up to antibody scale (~150kDa). In particular, the study will test...

Read more

ClearPoint Neuro Announces EU MDR Certification for ClearPoint Navigation Software Version 3.0.2, Expanding Access to the Latest Operating Room Navigation Platform in Europe

January 22, 2026 4:30 PM

ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced it has received EU MDR Certification for its ClearPoint Navigation Software Version 3.0.2. "By achieving CE Mark for the ClearPoint Navigation 3.0.2 software, we are able to unify our global navigation platform which we believe will enable consistent training and...

Read more

Moolec Science S.A. Receives Nasdaq Panel Exception Through June 29, 2026 to Regain Compliance with Stockholders' Equity Requirement

January 22, 2026 9:20 AM

Moolec Science S.A. ("Moolec" or the "Company") today announced that it has received a decision from the Nasdaq Hearings Panel (the "Panel") granting the Company an exception through June 29, 2026 to demonstrate compliance with the stockholders' equity requirement set forth in Nasdaq Listing Rule 5550(b)(1) (the "Stockholders' Equity Requirement"), subject to certain disclosure conditions. Following bankruptcy proceedings of certain of Moolec's...

Read more

IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trial Site at Integrative Clinical Trials in New York

January 22, 2026 9:00 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage pharmaceutical company leveraging Artificial Intelligence ("AI") to develop innovative treatments for Alzheimer's disease, today announced the addition of Integrative Clinical Trials, LLC, located in Brooklyn, New York, as a new clinical site participating in the Company's Phase 2 CALMA clinical trial evaluating IGC-AD1 for the treatment of agitation associated with...

Read more

Athos Therapeutics Receives US FDA Authorization to Begin Multi-Center Phase 2 Clinical Trial of ATH-063 in Patients with Ulcerative Colitis

January 21, 2026 11:30 AM

Athos Therapeutics, Inc. ("Athos"), an AI software and clinical stage biotechnology company pioneering the development of precision small molecule therapeutics for patients with immune-mediated diseases, announced today that it has been granted US FDA authorization to commence an international Phase 2 clinical trial of ATH-063 in patients with moderately to severely active, biologic-refractory ulcerative colitis. In addition to the main efficacy...

Read more

Hologenix Expands Its DTC Offerings With New Bedding Products

January 21, 2026 10:00 AM

Hologenix, the pioneer in infrared textile innovation and the company behind CELLIANT®, is excited to announce the launch of its latest infrared tech infused sleep product: The Celestial Sleep Sheets Powered by CELLIANT. Sleep is a crucial part of our health, and Hologenix is committed to helping consumers have more restful nights, which is exactly why the company is bringing more direct-to-consumer products to the market this year. Following a...

Read more

FluoGuide Submits an IND for FG001, to Initiate First U.S. Registration Trial

January 21, 2026 2:35 AM

FluoGuide A/S ("FluoGuide" or the "Company")(STO:FLUO), a biotech company maximizing surgical outcomes in oncology by lighting up cancer, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for FG001. The IND supports the initiation of the Company's first registration trial in patients with high-grade glioma (HGG). The IND submission represents a key regulatory...

Read more

Regentis' GelrinC Demonstrates Breakthrough in Regenerating Native-Like Cartilage Structure in Knee Repair on MRI Results Confirmed Using a Validated, Regulator-Accepted Method

January 20, 2026 8:33 AM

Regentis Biomaterials Ltd., ("Regentis" or the "Company") (NYSE American:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today announced new long-term imaging data from its successfully completed European clinical trial of GelrinC®, demonstrating that regenerated cartilage exhibits internal structural organization closely resembling healthy, native hyaline cartilage. The data, published in the peer-reviewed...

Read more

LIR Life Sciences Launches Comparative Animal Study to Advance Transdermal Delivery of Second Generation GLP/GIP-based Obesity Therapies

January 15, 2026 6:00 PM

LIR Life Sciences Corp. (CSE:SKNY)(OTC PINK:BBCMF)(Frankfurt:N790, WKN:A41QA9) ("LIR" or the "Company")is pleased to announce the launch of a controlled comparative animal study designed to evaluate cell-penetrating peptide (CPP) mediated, needle-free transdermal delivery of second generation GLP/GIP-based obesity therapies. This in vivo study represents an important next step towards advancing LIR's transdermal platform from design-stage...

Read more

enVVeno Medical Announces Reverse Stock Split

January 15, 2026 8:00 AM

enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced that the Company's Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1 for 35 (the "Reverse Stock Split"). The Reverse Stock Split will become effective at 12:01 a.m. Eastern time on January 20, 2026 and the Company's common stock will open for trading on The Nasdaq Capital Market on a post-split basis...

Read more

Adolore BioTherapeutics Announces FDA Orphan Drug Designation for its Kv7-activating rdHSV-CA8* Therapy in the Treatment of Erythromelalgia

January 14, 2026 5:40 PM

Adolore BioTherapeutics ("Adolore" or the "Company"), a biotechnology company focused on developing breakthrough treatments for neurological disorders, including chronic pain, with opioid-free locally-administered gene-therapies, today announced the FDA Office of Orphan Products Development has approved an Orphan Drug Designation, (ODD), for its innovative Kv7 activating rdHSV-CA8* gene therapy for treatment of primary and secondary...

Read more

Faron Pharmaceuticals Ltd: PDMR Dealing

January 13, 2026 11:15 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, announces today that Mr. Jurriaan Dekkers, Chief Financial Officer of the Company, sold 4,000 ordinary shares in Faron at price of £1.822 per share on 12 January 2026. Further details are set out in the Notification of Dealing Form below. PDMR Holding prior to sale Number of ordinary shares sold Resultant interest...

Read more

Lobe Sciences Advances Governance and Capital Markets Expertise with Appointment of Mr. Nick Karakochuk to the Board of Directors

January 13, 2026 7:00 AM

Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a clinical-stage biopharmaceutical company focused on advancing therapies for diseases with significant unmet medical needs, today announced the appointment of Mr. Nick Karakochuk, to its Board of Directors as the Company continues to build on the momentum established during fiscal 2025. Mr. Karakochuk is a corporate and securities lawyer at DuMoulin Black...

Read more